Asosiy kontentga oʻtish
Maqola

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

Andreas GreinacherInstitute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany;Kathleen SellengInstitute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany;Julia MayerleDepartment of Medicine II, University Hospital Munich, and German Centre for Infection Research (DZIF) (partner site Munich), Munich, Germany;Raghavendra PalankarInstitute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany;Jan WescheInstitute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany;Sven ReicheDepartment of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler Institut, Greifswald, Germany;Andrea AebischerDepartment of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler Institut, Greifswald, Germany;Theodore E. WarkentinDepartment of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, ON, Canada;Maximilian MuenchhoffMax von Pettenkofer Institute, Virology, Ludwig Maximilians University of Munich, and DZIF, Munich, Germany;Johannes C. HellmuthDepartment of Medicine III, University Hospital Munich, Munich, Germany;Oliver T. KepplerMax von Pettenkofer Institute, Virology, Ludwig Maximilians University of Munich, and DZIF, Munich, Germany;Daniel DuerschmiedHeart Center Freiburg University, Cardiology and Angiology I and Medical Intensive Care, Medical Center,Achim LotherInstitute of Experimental and Clinical Pharmacology and Toxicology, andSiegbert RiegDivision of Infectious Diseases, Department of Medicine II, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany;Meinrad GawazDepartment of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany;Karin Anne Lydia MuellerDepartment of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany;Christian ScheerMatthias NappKlaus HahnenkampGuglielmo LuccheseDepartment of Neurology, University Medicine Greifswald, Greifswald, Germany;Antje VogelgesangDepartment of Neurology, University Medicine Greifswald, Greifswald, Germany;Agnes FlöelDepartment of Neurology, University Medicine Greifswald, Greifswald, Germany;Piero LovreglioInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy; andAngela StufanoInterdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy; andRolf MarschalekInstitute of Pharmacology Biology, Biocenter, Goethe University, Frankfurt am Main, GermanyThomas ThieleInstitute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany;for the Immune-Response in COVID-19 Vaccination Study Group
2021en
ABI

Annotatsiya

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associated with unusual thrombosis. VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets through their FcγRIIa receptors. Antibodies that activate platelets through FcγRIIa receptors have also been identified in patients with COVID-19. These findings raise concern that vaccination-induced antibodies against anti-SARS-CoV-2 spike protein cause thrombosis by cross-reacting with PF4. Immunogenic epitopes of PF4 and SARS-CoV-2 spike protein were compared using in silico prediction tools and 3D modeling. The SARS-CoV-2 spike protein and PF4 share at least 1 similar epitope. Reactivity of purified anti-PF4 antibodies from patients with VITT was tested against recombinant SARS-CoV-2 spike protein. However, none of the affinity-purified anti-PF4 antibodies from 14 patients with VITT cross-reacted with SARS-CoV-2 spike protein. Sera from 222 polymerase chain reaction-confirmed patients with COVID-19 from 5 European centers were tested by PF4-heparin enzyme-linked immunosorbent assays and PF4-dependent platelet activation assays. We found anti-PF4 antibodies in sera from 19 (8.6%) of 222 patients with COVID-19. However, only 4 showed weak to moderate platelet activation in the presence of PF4, and none of those patients developed thrombotic complications. Among 10 (4.5%) of 222 patients who had COVID-19 with thrombosis, none showed PF4-dependent platelet-activating antibodies. In conclusion, antibodies against PF4 induced by vaccination do not cross-react with the SARS-CoV-2 spike protein, indicating that the intended vaccine-induced immune response against SARS-CoV-2 spike protein is not the trigger of VITT. PF4-reactive antibodies found in patients with COVID-19 in this study were not associated with thrombotic complications.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba